Cargando…

Monoamine Reuptake Inhibitors in Parkinson's Disease

The motor manifestations of Parkinson's disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huot, Philippe, Fox, Susan H., Brotchie, Jonathan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355567/ https://www.ncbi.nlm.nih.gov/pubmed/25810948 http://dx.doi.org/10.1155/2015/609428

Ejemplares similares

Monoamine depletion by reuptake inhibitors
por: Hinz, Marty, et al.
Publicado: (2011)

The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
por: Huot, Philippe, et al.
Publicado: (2012)

Monoamine Depletion by Reuptake Inhibitors [Retraction]
Publicado: (2020)

Monoamine Depletion by Reuptake Inhibitors [Expression of Concern]
Publicado: (2020)

Implications for Combination Therapy of Selective Monoamine Reuptake Inhibitors on Dopamine Transporters
por: Ahn, Hyomin, et al.
Publicado: (2023)

Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats
por: Baarendse, Petra J. J., et al.
Publicado: (2011)

Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence
por: Müller, Thomas
Publicado: (2021)

Chirality Matters: Fine-Tuning of Novel Monoamine Reuptake Inhibitors Selectivity through Manipulation of Stereochemistry
por: Kalaba, Predrag, et al.
Publicado: (2023)

Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2022)

A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD
por: Wilens, Timothy E, et al.
Publicado: (2008)

Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
por: Koprich, James B., et al.
Publicado: (2011)

The effect of monoamines reuptake inhibitors on aerobic exercise performance in bank voles from a selection experiment
por: Jaromin, Ewa, et al.
Publicado: (2019)

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
por: Tan, Yu-Yan, et al.
Publicado: (2022)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

Antidepressant stimulation of CDP-diacylglycerol synthesis does not require monoamine reuptake inhibition
por: Aboukhatwa, Marwa A, et al.
Publicado: (2010)

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease
por: Robottom, Bradley J
Publicado: (2011)

Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays
por: Zwartsen, Anne, et al.
Publicado: (2020)

Relative Contributions of Norepinephrine and Serotonin Transporters to Antinociceptive Synergy between Monoamine Reuptake Inhibitors and Morphine in the Rat Formalin Model
por: Shen, Fei, et al.
Publicado: (2013)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Common network effect-patterns after monoamine reuptake inhibition in dissociated hippocampus cultures
por: Trepl, Julia, et al.
Publicado: (2022)

Correction to: Common network effect‑patterns after monoamine reuptake inhibition in dissociated hippocampus cultures
por: Trepl, Julia, et al.
Publicado: (2022)

Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008)

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
por: Alborghetti, Marika, et al.
Publicado: (2019)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
por: Naoi, Makoto, et al.
Publicado: (2022)

Pros and cons of a prion-like pathogenesis in Parkinson's disease
por: Hilker, Ruediger, et al.
Publicado: (2011)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011)

Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors
por: Lee, Jimin, et al.
Publicado: (2022)

Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease
por: Ye, Zheng, et al.
Publicado: (2014)

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2013)

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors
por: Chiuccariello, Lina, et al.
Publicado: (2015)

The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials
por: Azizi, Marzieh, et al.
Publicado: (2022)

Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2021)

Candidate genes for antidepressant response to selective serotonin reuptake inhibitors
por: Lotrich, Francis E, et al.
Publicado: (2005)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
por: Fanelli, David, et al.
Publicado: (2021)

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
por: Nguyen, Thanh Thanh L., et al.
Publicado: (2021)

Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action
por: Rinaldi, Domiziana, et al.
Publicado: (2023)

The pons and human affective processing — Implications for Parkinson's disease
por: Huot, Philippe
Publicado: (2015)

ABUSE OF MONOAMINE OXIDASE INHIBITORS
por: Ananth, Jambur, et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_9cfrjmcq69o0ft9t9b1k3rh8k8